As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Kennedy believes that vaccines cause autism and wants to use his perch to carry out further testing.

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

The S&P 500, Nasdaq and Dow all fell for the week, while pharmaceutical stocks slid after Trump picked anti-vaccine activist ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.